secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001558370-22-018228
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.03, 3.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharma raises up to $31M in private placement; submits IND for KPI-012
---------------------------------------------------------------------------

- First closing gross proceeds ~$6M: 76,813 common shares at $5.75 and 9,666 Series E preferred shares at $575 each.
- Second closing ~$25M (Series E preferred) contingent on FDA acceptance of IND for KPI-012 by March 31, 2023.
- IND submitted for KPI-012 to treat persistent corneal epithelial defects; Phase 2b trial start in Q4 2022, topline data expected Q1 2024.
- Cash runway extended into Q1 2025 assuming both closings occur.
- Series E preferred stock convertible into common at 100:1, senior to common; all outstanding Series D preferred eliminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837022018228/0001558370-22-018228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837022018228/kala-20221128x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-018228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer